oral semaglutide for Weight-loss ACC 2025: Oral Semaglutide Reduces

Called liraglutide and sold under the brand name Saxenda, the weekly injectable led to a nearly 3 percent reduction in body weight on average in trial participants who took it

doi: 10.5014/ajot.2019.024612

With Tirzepatide (Zepbound) now having FDA approval for obesity, rumblings have again started about whether there will be increased price pressure and perhaps a reduction in cost for GLP-1s, which could bring increased access

The most common side effect of GLP-1 agonists is nausea

In addition, people have been getting IVs for almost 200 years

The takeaway from these studies: Obesity is a chronic condition and without ongoing treatment (whether medication, surgery, or intensive behavioral support), biology will try to pull weight back up